Article
Rheumatology
Gerasimos Evangelatos, George E. Fragoulis, Kalliopi Klavdianou, Melina Moschopoulou, Dimitrios Vassilopoulos, Alexios Iliopoulos
Summary: The study found that 43% of rheumatoid arthritis patients treated with RTX developed HGG. Patients who developed low IgG or low IgM had lower baseline levels than those who did not, and the development of low IgM was associated with better disease outcomes.
Article
Rheumatology
Siddharth Jain, Varun Dhir, Amita Aggarwal, Ranjan Gupta, Bidyalaxmi Leishangthem, Shankar Naidu, Aastha Khullar, Supriya Maurya, Veena Dhawan, Shefali Khanna Sharma, Aman Sharma, Sanjay Jain
Summary: This study compared the efficacy and safety of different dose escalation strategies of oral MTX in RA patients over a period of 16-24 weeks. The results showed that a faster escalation strategy was not more effective than the usual strategy, but was associated with higher gastrointestinal adverse events in the initial phase.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Rheumatology
Dzenan Masic, Kristian Stengaard-Pedersen, Brian Bridal Logstrup, Kim Horslev-Petersen, Merete Lund Hetland, Peter Junker, Mikkel ostergaard, Christian Ammitzboll, Soren Moller, Robin Christensen, Torkell Ellingsen
Summary: In patients with rheumatoid arthritis, there were no significant differences in lipid level changes between those treated with adalimumab plus methotrexate and those treated with placebo plus methotrexate over a 1-year period. The study suggests that both treatment strategies have similar effects on lipid levels in early and treatment-naive RA patients.
RHEUMATOLOGY INTERNATIONAL
(2021)
Article
Immunology
Liyan Mei, Zhihua Yang, Xiaolin Zhang, Zehao Liu, Maojie Wang, Xiaodong Wu, Xiumin Chen, Qingchun Huang, Runyue Huang
Summary: This study investigated the changes in gut microbiome of RA patients treated with HQT or LEF, revealing significant differences in gut microbiota between RA patients and healthy controls. The clinical efficacy of the two treatments was similar, but the response trends of RA-related clinical indices differed between the two treatment groups.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Rheumatology
Carlo Scognamiglio Renner Araujo, Ana Cristina Medeiros-Ribeiro, Carla G. S. Saad, Karina Rossi Bonfiglioli, Diogo Souza Domiciano, Andrea Yukie Shimabuco, Matheus Santos Rodrigues Silva, Emily Figueiredo Neves Yuki, Sandra Gofinet Pasoto, Tatiana Pedrosa, Leonard de Vinci Kanda Kupa, Gioanna Zou, Rosa M. R. Pereira, Clovis Artur Silva, Nadia Emi Aikawa, Eloisa Bonfa
Summary: This study evaluated the effect of discontinuing methotrexate (MTX) for 2 weeks after each dose of the Sinovac-CoronaVac vaccine on immunogenicity and safety in patients with rheumatoid arthritis (RA). The results showed that the group that discontinued MTX had a higher rate of seroconversion and higher antibody titers compared to the group that continued MTX. However, there was an increased risk of flare after the second MTX withdrawal.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Andreas Kerschbaumer, Zaida Iasha Rivai, Josef S. Smolen, Daniel Aletaha
Summary: This study analyzed the response differences in patients with rheumatoid arthritis receiving placebo treatment, comparing those who continued background therapy with methotrexate (MTX) and those without any disease modifying antirheumatic drugs (DMARDs). The results showed that placebo responses were higher in patients who continued MTX background therapy, suggesting a more consequent intake of background therapy during the trial period.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Paul Studenic, Daniel Aletaha, Maarten de Wit, Tanja A. Stamm, Farideh Alasti, Diane Lacaille, Josef S. Smolen, David T. Felson
Summary: This study aimed to externally validate a revised Boolean remission criteria using a higher patient global assessment (PtGA) threshold and validate the provisionally endorsed index-based criteria. The results showed that using the higher PtGA threshold increased the proportion of patients classified as achieving remission under the "Boolean2.0" criteria, improved agreement with index-based criteria, and did not compromise predictive value for radiographic or functional outcomes. The study findings were endorsed by ACR and EULAR.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Margaret H. Chang, Alexandra Bocharnikov, Siobhan M. Case, Marc Todd, Jessica Laird-Gion, Maura Alvarez-Baumgartner, Peter A. Nigrovic
Summary: This study aims to identify patient-specific patterns of joint flare in inflammatory arthritides to distinguish local from systemic drivers of disease chronicity. The results showed that arthritis flares preferentially affect previously inflamed joints and carry an ongoing risk of disease extension. These findings confirm joint-specific memory and suggest that prevention of new joint accumulation should be an important target for arthritis therapy.
ARTHRITIS & RHEUMATOLOGY
(2022)
Article
Rheumatology
Helga Westerlind, Bente Glintborg, Hilde Berner Hammer, Saedis Saevarsdottir, Niels Steen Krogh, Merete Lund Hetland, Ellen-Margrethe Hauge, Isabel Martinez Tejada, Joseph Sexton, Johan Askling
Summary: This study aims to describe how data harmonization can be achieved in rheumatoid arthritis (RA) and found that the proportion of patients reaching remission in RA treatment is low.
Article
Rheumatology
Richard A. Furie, Gustavo Aroca, Matthew D. Cascino, Jay P. Garg, Brad H. Rovin, Analia Alvarez, Hilda Fragoso-Loyo, Elizabeth Zuta-Santillan, Thomas Schindler, Paul Brunetta, Cary M. Looney, Imran Hassan, Ana Malvar
Summary: This study compared the efficacy of obinutuzumab with standard therapies and placebo in the treatment of LN. The results showed that obinutuzumab achieved better complete renal responses at 52 and 104 weeks compared to standard therapies alone. It also showed improvements in other renal response measures, serologies, estimated glomerular filtration rate and proteinuria. Obinutuzumab was well tolerated and no new safety signals were identified.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Chemistry, Multidisciplinary
Moonkyoung Jeong, Yuna Jung, Junyong Yoon, Jinyoung Kang, Seo Hyeon Lee, Woojin Back, Hyoyeon Kim, Michael J. Sailor, Dokyoung Kim, Ji-Ho Park
Summary: A porous silicon-based nanomedicine is developed to deliver an antirheumatic drug to inflamed synovium and degrade into bone-remodeling products. The nanomedicine shows immunomo-dulatory and antiresorptive effects, and effectively ameliorates the progression of rheumatoid arthritis in a mouse model.
Article
Oncology
Nadine Kirsch-Stefan, Elena Guillen, Niklas Ekman, Sean Barry, Verena Knippel, Sheila Killalea, Martina Weise, Elena Wolff-Holz
Summary: The study found that in 67% of cases, the outcomes of quality and clinical assessments aligned, either supporting or not supporting approval. Major objections were identified in the quality part in 11% of cases, while 22% of cases had major objections raised in the clinical data package. However, no negative overall decisions were solely based on seemingly negative clinical data, suggesting that clinical trials were not essential in resolving uncertainties related to quality in biosimilar evaluations.
Article
Immunology
Iris Paola Guzman-Guzman, Claudia Isabel Ramirez-Velez, Ramces Falfan-Valencia, Jose Eduardo Navarro-Zarza, Ilse Adriana Gutierrez-Perez, Oscar Zaragoza-Garcia, Monica Ramirez, Natividad Castro-Alarcon, Isela Parra-Rojas
Summary: The SNP of the PADI2 gene plays a crucial role in the pathogenesis and severity of rheumatoid arthritis (RA), with specific genotypes in women from southern Mexico being associated with early disease onset, positive autoantibodies, and radiographic joint damage.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Rheumatology
Renske C. F. Hebing, Marry Lin, Maja Bulatovic Calasan, Ittai B. Muller, Sohaila Mahmoud, Sandra Heil, Eduard A. Struys, Bart J. F. van den Bemt, Jos W. R. Twisk, Willem Lems, Michael T. Nurmohamed, Gerrit Jansen, Robert de Jonge
Summary: This study investigates the pharmacokinetics of methotrexate polyglutamate (MTX-PG) accumulation in red blood cells (RBCs) and peripheral blood mononuclear cells (PBMCs) in patients with early rheumatoid arthritis (RA) after oral and subcutaneous MTX treatment. The results show that there are disparate pharmacokinetic profiles between PBMCs and RBCs, with higher accumulation of MTX-PG in PBMCs. The distribution profile of MTX-PG in PBMCs remains constant over 6 months, while in RBCs, the main PG-moiety changes from MTX-PG(1) to MTX-PG(3).
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Mikkel Ostergaard, Ronald F. van Vollenhoven, Anna Rudin, Merete Lund Hetland, Marte Schrumpf Heiberg, Dan C. Nordstrom, Michael T. Nurmohamed, Bjorn Gudbjornsson, Lykke Midtboll Ornbjerg, Pernille Boyesen, Kristina Lend, Kim Horslev-Petersen, Till Uhlig, Tuulikki Sokka, Gerdur Grondal, Simon Krabbe, Joakim Lindqvist, Inger Gjertsson, Daniel Glinatsi, Meliha Crnkic Kapetanovic, Anna-Birgitte Aga, Francesca Faustini, Pinja Parmanne, Tove Lorenzen, Cagnotto Giovanni, Johan Back, Oliver Hendricks, Daisy Vedder, Tuomas Rannio, Emma Grenholm, Maud Kristine Ljosa, Eli Brodin, Hanne Lindegaard, Annika Soderbergh, Milad Rizk, Alf Kastbom, Per Larsson, Line Uhrenholt, Soren Andreas Just, David J. Stevens, Trine Bay Laurbjerg, Gunnstein Bakland, Inge Christoffer Olsen, Espen A. Haavardsholm, Jon Lampa, NORD-STAR Study Grp
Summary: This study compared the clinical and radiographic outcomes of different biological treatments with active conventional therapy in patients with early rheumatoid arthritis (RA). The results showed that abatacept and certolizumab pegol had higher clinical remission rates compared to active conventional therapy, while tocilizumab did not show significant differences. Radiographic progression was low and similar across treatments.
ANNALS OF THE RHEUMATIC DISEASES
(2023)